Shanxi Jinbo Bio-Pharmaceutical Co., Ltd.

Achieving healthy, functional endothelialization represents the goal of neointima healing in cardiovascular implants but remains challenging due to strategies that fail to adapt dynamically to complex material-tissue interactions. We develop a biomimetic coating with dynamic stiffness via layer-by-layer assembly of recombinant humanized type III collagen and cystamine-modified hyaluronic acid, followed by postcrosslinking. The coating incorporates ECM-mimetic components and exhibits tunable stiffness that dynamically decreases in response to microenvironmental stimuli such as glutathione and reactive oxygen species. It exhibits stage-specific properties: initially suppressing acute thrombosis and directing cell adhesion; then facilitating a confluent, functional endothelial monolayer; driving smooth muscle cell contractile phenotype; and inducing anti-inflammatory macrophage polarization. In vivo, stents coated with our coating suppressed neointimal hyperplasia, achieving neointimal healing with morphology and function resembling native endothelium at 12 months. These findings reveal how dynamic stiffness guides material-tissue responses and provide a promising approach to enhance vascular implant healing.

Collagen is valued for its nutritional and functional properties but is limited in food applications due to instability and digestive degradation. To overcome these limitations, this study developed a liposome-based collagen delivery system (Lip-COL) and systematically evaluated its physicochemical and functional characteristics. Lip-COL displayed spherical morphology, a mean particle size of 215.13 ± 1.42 nm, a zeta potential of -18.87 ± 0.29 mV, an encapsulation efficiency of 70.13 ± 0.39%, and pseudoplastic flow behavior. Encapsulation markedly improved collagen stability against heat, pH, and ionic strength. In vitro release and simulated digestion demonstrated sustained release, with delayed t50 (1.1 h) and t80 (7.7 h), and a 26% reduction in burst release, ensuring intestinal-phase delivery while preserving antioxidant activity. These findings highlight liposomal encapsulation as an effective nutraceutical nanodelivery strategy to enhance collagen stability and biofunctionality, supporting its potential as a dietary supplement and functional food ingredient.

Progesterone resistance in fertility-preserving patients with endometrial cancer (EC) remains a significant challenge, and radiomics has not yet been used to predict progestin therapy in these cases.

In this study, we constructed a radiomics model to predict progesterone resistant for fertility preservation patients. Distribution of clinical features have significant differences in the high and low risk of progesterone-resistant subgroups, which we call predicting-sensitive (PS) versus predicting-resistant (PR) subgroups. The radiomics model achieved high predictive accuracy with an area under the receiver operating characteristic curve (AUC) of 0.841 in the training cohort. We further validate this model in the validation and whole cohorts. As a result, the AUCs were 0.873 and 0.852, respectively. The identified key biological pathways include cellular response to external stimulus, collagen metabolic processes, and extracellular matrix (ECM) remodeling. PS was strongly linked to higher type III collagen content and changes in ECM stiffness, which were reflected in altered tumor microenvironment dynamics. Finally, we confirmed that the PR subgroup exhibited increased cellular stiffness by microfluidic device. Exogenous supplementation of COL III enhanced the sensitivity of EC cells to progesterone and reduced cell stiffness.

Our radiomics model provides a promising, noninvasive tool for predicting progesterone resistance in EC. This approach paves the way for personalized therapeutic strategies for fertility-preserving patients.